Table 2.

Association of genetically predicted age at menarche with CRC risk according to subgroups, CCFR, GECCO Consortium

Subgroup	N (cases/controls)	ORa	95% CI	P-value	Heterogeneity P-valueb
All	5832/6285	0.97	0.92–1.02	0.20
Menopausal status
Premenopausal	545/621	0.95	0.80–1.12	0.54	0.94
Postmenopausal	5263/5647	0.97	0.92–1.02	0.23
Menopausal hormone therapy combined
No	3266/3490	0.96	0.90–1.03	0.24	0.69
Yes	593/807	0.98	0.85–1.14	0.82
Oestrogen monotherapy
No	3120/3214	0.94	0.88–1.01	0.11	0.17
Yes	716/1088	1.04	0.91–1.19	0.55
Site
Colon	4037/6285	0.97	0.91–1.02	0.26	0.25c
Rectum	1184/6285	1.04	0.95–1.14	0.36

CCFR Colon Cancer Family Registry, CI confidence interval, GRS genetic risk score, OR odds ratio per year

^aAll analyses adjusted for age, sex, study, and principal components of genetic ancestry

^bP-value calculated using likelihood ratio tests comparing the model with and without interaction term

^cP-value for heterogeneity was obtained in case-only analysis of colon vs. rectal cancer